TICKERNERD
Menu
GANXGANXHealthcare · Biotechnology

GANX Stock Forecast: Gain Therapeutics, Inc. Price Predictions for 2026-2027

Last close, 11 Sept 2026
$1.75
+2.34% on the day

The 5 Wall Street analysts covering Gain Therapeutics, Inc. hold a median 12-month price target of $8 — +357.1% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 31 of 100 as at 10 Sept 2026 — in the lower half. The Street sees upside; the factor read is a caution. That gap is the story on this page.

Market cap
$75.1M
Ticker Nerd rank
31 / 100
Median analyst target
$8.00
Analysts covering
5
Revenue$0.0
Operating income−$4.7M
Net income−$4.7M
Free cash flow−$4.7M
Quarterly, 8 quarters to 30 June 2026 · latest quarter's figure shown
Total return, dividends reinvested
1W
−3.8%
1M
−15.0%
YTD
−45.7%
1Y
+1.7%
From 52W high
−58.1%
From 52W low
+10.8%
$1.58
$4.18
52-week range, adjusted closes · the dot is the last close
Ticker Nerd rank

GANX stock analysis: one number for the whole business

Consensus tells you what everyone already believes. The model scores Gain Therapeutics, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 10 Sept 2026
31 / 100

Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Size
79
Revisions
73
Momentum
47
Issuance
38
Accruals
33
Value
33
Growth
31
Volatility
21
Quality
16

Size (79): Smaller than most of the companies we track.

Quality (16): Profits are thin or unreliable for the size of the business, or they are not turning into cash.

Built and run by Aslam Ghouse, an ex-Goldman Sachs quant trader with fourteen years in markets.

Wall Street

GANX stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on GANX, reported as data — targets and ratings, the market's view beside the model's.

Share price and the analyst range, 12 monthsAdjusted close, US dollars
$2.00$4.00$6.00$8.00Oct 25Jan 26Apr 26Jul 26GANXHigh $8.00Median $8.00Low $5.00

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Data provided by Twelve Data

What Wall Street says5 analysts
5 Buy0 Hold0 Sell
Low $5.00Median $8.00High $8.00

The green dot is the last close — the median target sits +357.1% from it.

Recent analyst actionsNewest first
DateFirmActionRatingTarget
31 Aug 2026HC Wainwright & Co.ReiteratesBuy$8.00
11 Aug 2026BTIGReiteratesBuy$5.00
11 Aug 2026BTIGReiteratesBuy—
1 July 2026HC Wainwright & Co.ReiteratesBuy$8.00
1 July 2026HC Wainwright & Co.ReiteratesBuy—
30 June 2026BTIGMaintainsBuy$5.00
30 June 2026BTIGMaintainsBuy—
19 Dec 2025HC Wainwright & Co.ReiteratesBuy—
15 Oct 2025BTIGReiteratesBuy—
13 Oct 2025HC Wainwright & Co.ReiteratesBuy—
7 Oct 2025Maxim GroupMaintainsBuy—
8 Sept 2025BTIGReiteratesBuy—
13 Aug 2025Roth CapitalMaintainsBuy—
3 July 2025HC Wainwright & Co.ReiteratesBuy—
19 May 2025HC Wainwright & Co.ReiteratesBuy—
28 Mar 2025Chardan CapitalMaintainsBuy—
17 Mar 2025HC Wainwright & Co.ReiteratesBuy—
7 Mar 2025ScotiabankInitiatesSector Outperform—
24 Dec 2024Roth MKMMaintainsBuy—
5 Dec 2024Roth MKMInitiatesBuy—

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Market Radar

This page is one stock. Monday covers all of them.

Computed off the Friday close and sent before the US open.

Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. GANX appears on the weeks it earns a place.

Free, every Monday. Unsubscribe any time.

Performance

GANX vs the S&P 500

Both lines are total return — dividends reinvested — so the comparison is honest on both sides.

Over the twelve months to 11 Sept 2026, Gain Therapeutics, Inc. returned +1.7% against +17.5% for the S&P 500, dividends included.

GANX vs S&P 500, last 12 monthsTotal return, rebased to 100
100150200250Oct 25Jan 26Apr 26Jul 26GANXS&P 500

Download this chart as an image — free to reuse; link this page as the source.

Data provided by Twelve Data

Estimates

GANX analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Which way the estimates are movingNext fiscal year
Analysts raising
1
Analysts cutting
0
Fundamentals

Gain Therapeutics, Inc. (GANX) financial data

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation
Trailing P/E
−2.8×

Cheaper than 87% of US stocks

Price / sales
—
Price / book
6.6×

Cheaper than 15% of US stocks

EV / EBITDA
−3.3×

Cheaper than 75% of US stocks

Growth & margins
Revenue growth (YoY)
—
Earnings growth (YoY)
—
Gross margin
—
Operating margin
0.0%

Higher than 32% of US stocks

Net margin
0.0%

Higher than 30% of US stocks

Returns & dividend
Return on equity
−268.3%

Higher than 5% of US stocks

Return on assets
−95.5%

Higher than 3% of US stocks

Dividend yield
—

Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.

Key statistics

Gain Therapeutics, Inc. (GANX) statistics: revenue, profit & scale

The headline figures, each with its date. Every row carries its own link — cite it straight from here.

  • Gain Therapeutics, Inc. has a market value of $75.1M and an enterprise value of $62.6M.

  • Revenue in the twelve months to 30 June 2026: $0.0.

  • Net income over the same four quarters: −$20.1M.

  • Free cash flow in the twelve months to 30 June 2026: −$19.0M.

  • Shares outstanding: 42.7M.

  • Trailing P/E: −2.8×; forward P/E: −3.1× — the forward figure prices analyst consensus estimates, not reported earnings.

  • Gain Therapeutics, Inc. employs 20 people.

Statement figures: company filings via Twelve Data, four quarters to 30 June 2026 · market figures as at 10 Sept 2026

Data provided by Twelve Data

Peers

GANX vs competitors

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelBiotechnology
CompanyMarket capTKN rank
GANXGain Therapeutics, Inc.$75.1M
31
TENXTenax Therapeutics, Inc.$73.0M
23
NTRBNutriband, Inc.$73.9M
31
NRXSNeurAxis, Inc.$70.5M
54
CSBRChampions Oncology, Inc.$70.3M
27
BSEMBioStem Technologies, Inc.$74.5M
55
IBIOiBio, Inc.$74.5M
26

Look up any of the roughly 4,600 stocks we score.

The rank is the raw material. Whether the rules would actually own Gain Therapeutics, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →

News

Latest GANX news & analysis

Gain Therapeutics to Participate at H.C. Wainwright 28th Annual Global Investment Conference

GlobeNewsWire · 25 Aug 2026neutral

Gain Therapeutics announced that President and CEO Gene Mack will participate in one-on-one meetings at the H.C. Wainwright 28th Annual Global Investment Conference. The announcement was made on August 25, 2026.

Why it matters — A GANX watcher would care because the CEO's participation at a major investment conference provides an opportunity for the company to present its pipeline to investors and analysts.

FAQ

Frequently asked questions about GANX stock

What is the GANX stock price forecast for 2026-2027?

The 5 Wall Street analysts covering Gain Therapeutics, Inc. have a median 12-month price target of $8, with estimates ranging from $5 to $8. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.

Is GANX stock a buy right now?

Of the 5 analysts covering Gain Therapeutics, Inc., 5 rate it a Buy, 0 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Gain Therapeutics, Inc. 31 out of 100 across roughly 4,600 US stocks as at 10 Sept 2026. None of this is personal advice — it does not consider your circumstances.

How does Ticker Nerd's model rank GANX?

As at 10 Sept 2026, Gain Therapeutics, Inc. ranks 31 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Size (79 of 100).

Will GANX stock go up?

No one can know that. What the data says: the median 12-month target from 5 analysts implies +357.1% from the last close, and Ticker Nerd's factor model ranks Gain Therapeutics, Inc. 31 out of 100 as at 10 Sept 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.

What is the GANX stock forecast for 2030?

No analyst covering Gain Therapeutics, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for GANX are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $5 to $8 over the next 12 months.

How has GANX stock performed over the past year?

Gain Therapeutics, Inc. returned +1.7% over the 12 months to 11 Sept 2026, with dividends reinvested. Past performance does not indicate future returns.

What does Gain Therapeutics, Inc. do?

Gain Therapeutics, Inc. is a clinical-stage biotechnology company focused on discovering and developing allosteric small molecule therapies for difficult-to-treat diseases.

What is the latest news on GANX?

The most recent item we track (GlobeNewsWire, 25 Aug 2026): "Gain Therapeutics to Participate at H.C. Wainwright 28th Annual Global Investment Conference". Gain Therapeutics announced that President and CEO Gene Mack will participate in one-on-one meetings at the H.C. Wainwright 28th Annual Global Investment Conference. The announcement was made on August 25, 2026.

Company

About Gain Therapeutics, Inc.

Gain Therapeutics, Inc. is a clinical-stage biotechnology company focused on discovering and developing allosteric small molecule therapies for difficult-to-treat diseases. Its current research centers on neurodegenerative disorders and other conditions linked to protein misfolding, with a particular emphasis on Parkinson’s disease and select rare genetic diseases. The company’s lead candidate, GT-02287, is being evaluated for Parkinson’s disease and is part of a broader pipeline aimed at addressing underlying disease mechanisms rather than only managing symptoms. Gain Therapeutics also uses its Magellan drug discovery platform to identify novel allosteric binding sites and design proprietary compounds with the potential to modulate protein function. Headquartered in Bethesda, Maryland, Gain Therapeutics operates as a specialized player in precision medicine and computational drug discovery within the biotechnology sector.

CEO Mr. Gene Mack M.B.A. · 20 employees · United States · https://gaintherapeutics.com